1. Miranda-Filho A, Bray F. Global patterns and trends in cancers of the lip, tongue and mouth. Oral Oncol. 2020;102:104551.

https://doi.org/10.1016/j.oraloncology.2019.104551

PMid:31986342 

2. Warnakulasuriya S. Global epidemiology of oral and oropharyngeal cancer. Oral Oncol. 2009;45:309-16.

https://doi.org/10.1016/j.oraloncology.2008.06.002

PMid:18804401 

3. Warnakulasuriya S, Kujan O, Aguirre-Urizar JM, Bagan JV, González-Moles M, Kerr AR, et al. Oral potentially malignant disorders: A consensus report from an international seminar on nomenclature and classification, convened by the WHO Collaborating Centre for Oral Cancer. Oral Dis. 2020.

https://doi.org/10.1111/odi.13704

PMid:33128420 

4. Gaykalova DA, Mambo E, Choudhary A, Houghton J, Buddavarapu K, Sanford T, et al. Novel insight into mutational landscape of head and neck squamous cell carcinoma. PLoS One. 2014;9:e93102.

https://doi.org/10.1371/journal.pone.0093102

PMid:24667986 PMCid:PMC3965530

5. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646-74.

https://doi.org/10.1016/j.cell.2011.02.013

PMid:21376230 

6. Nikitakis NG, Pentenero M, Georgaki M, Poh CF, Peterson DE, Edwards P, et al. Molecular markers associated with development and progression of potentially premalignant oral epithelial lesions: Current knowledge and future implications. Oral Surg Oral Med Oral Pathol Oral Radiol. 2018;125:650-69.

https://doi.org/10.1016/j.oooo.2018.03.012

PMid:29709496 

7. Chai AWY, Lim KP, Cheong SC. Translational genomics and recent advances in oral squamous cell carcinoma. Semin Cancer Biol. 2020;61:71-83.

https://doi.org/10.1016/j.semcancer.2019.09.011

PMid:31542510 

8. Farah CS. Molecular, genomic and mutational landscape of oral leukoplakia. Oral Diseases. 2021;27:803-12.

https://doi.org/10.1111/odi.13608

PMid:33448555 

9. Teixeira JH, Silva P, Faria J, Ferreira I, Duarte P, Delgado ML, et al. Clinicopathologic significance of BubR1 and Mad2 overexpression in oral cancer. Oral Dis. 2015;21:713-20.

https://doi.org/10.1111/odi.12335

PMid:25754611 

10. Griffis ER, Stuurman N, Vale RD. Spindly, a novel protein essential for silencing the spindle assembly checkpoint, recruits dynein to the kinetochore. J Cell Biol. 2007;177:1005-15.

https://doi.org/10.1083/jcb.200702062

PMid:17576797 PMCid:PMC2064361

11. Silva PMA, Delgado ML, Ribeiro N, Florindo C, Tavares ÁA, Ribeiro D, et al. Spindly and Bub3 expression in oral cancer: Prognostic and therapeutic implications. Oral Dis. 2019;25:1291-301.

https://doi.org/10.1111/odi.13089

PMid:30866167 

12. Kujan O, Oliver RJ, Khattab A, Roberts SA, Thakker N, Sloan P. Evaluation of a new binary system of grading oral epithelial dysplasia for prediction of malignant transformation. Oral Oncol. 2006;42:987-93.

https://doi.org/10.1016/j.oraloncology.2005.12.014

PMid:16731030 

13. Chaturvedi AK, Udaltsova N, Engels EA, Katzel JA, Yanik EL, Katki HA, et al. Oral Leukoplakia and Risk of Progression to Oral Cancer: A Population-Based Cohort Study. J Natl Cancer Inst. 2020;112:1047-54.

https://doi.org/10.1093/jnci/djz238

PMid:31860085 PMCid:PMC7566351

14. Villa A, Celentano A, Glurich I, Borgnakke WS, Jensen SB, Peterson DE, et al. World Workshop on Oral Medicine VII: Prognostic biomarkers in oral leukoplakia: A systematic review of longitudinal studies. Oral Dis. 2019;25 Suppl 1:64-78.

https://doi.org/10.1111/odi.13087

PMid:31140698 PMCid:PMC6544170

15. Monteiro L, Mello FW, Warnakualsuryia S. Tissue Biomarkers for Predicting the Risk of Oral Cancer in Patients Diagnosed with Oral Leukoplakia. A Systematic Review. Oral Dis. 2020.

https://doi.org/10.1111/odi.13747

PMid:33290585 

16. Choi JW, Kim Y, Lee JH, Kim YS. High expression of spindle assembly checkpoint proteins CDC20 and MAD2 is associated with poor prognosis in urothelial bladder cancer. Virchows Arch. 2013;463:681-7.

https://doi.org/10.1007/s00428-013-1473-6

PMid:23995871 

17. McGrogan B, Phelan S, Fitzpatrick P, Maguire A, Prencipe M, Brennan D, et al. Spindle assembly checkpoint protein expression correlates with cellular proliferation and shorter time to recurrence in ovarian cancer. Hum Pathol. 2014;45:1509-19.

https://doi.org/10.1016/j.humpath.2014.03.004

PMid:24792619 

18. Hsieh PC, Chen YK, Tsai KB, Shieh TY, Chang YY, Chang JG, et al. Expression of BUBR1 in human oral potentially malignant disorders and squamous cell carcinoma. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2010;109:257-67.

https://doi.org/10.1016/j.tripleo.2009.08.014

PMid:19926498 

19. Sravya T, Sivaranjani Y, Rao GV. Immunohistochemical expression of budding uninhibited by benzimidazole related 1 in leukoplakia and oral squamous cell carcinoma. J Oral Maxillofac Pathol. 2016;20:71-7.

https://doi.org/10.4103/0973-029X.180938

PMid:27194865 PMCid:PMC4860940

20. Chou CK, Wu CY, Chen JY, Ng MC, Wang HM, Chen JH, et al. BubR1 Acts as a Promoter in Cellular Motility of Human Oral Squamous Cancer Cells through Regulating MMP-2 and MMP-9. Int J Mol Sci. 2015;16:15104-17.

https://doi.org/10.3390/ijms160715104

PMid:26151845 PMCid:PMC4519889

21. Warnakulasuriya S, Kovacevic T, Madden P, Coupland VH, Sperandio M, Odell E, et al. Factors predicting malignant transformation in oral potentially malignant disorders among patients accrued over a 10-year period in South East England. J Oral Pathol Med. 2011;40:677-83.

https://doi.org/10.1111/j.1600-0714.2011.01054.x

PMid:21762430 

22. Speight PM, Khurram SA, Kujan O. Oral potentially malignant disorders: risk of progression to malignancy. Oral Surg Oral Med Oral Pathol Oral Radiol. 2018;125:612-27.

https://doi.org/10.1016/j.oooo.2017.12.011

PMid:29396319 

23. Dost F, Le Cao KA, Ford PJ, Farah CS. A retrospective analysis of clinical features of oral malignant and potentially malignant disorders with and without oral epithelial dysplasia. Oral Surg Oral Med Oral Pathol Oral Radiol. 2013;116:725-33.

https://doi.org/10.1016/j.oooo.2013.08.005

PMid:24144993 

24. Hannisdal K, Burum-Auensen E, Schjølberg A, De Angelis PM, Clausen OPF. Correlation between reduced expression of the spindle checkpoint protein BubR1 and bad prognosis in tonsillar carcinomas. Head Neck. 2010;32:1354-62.

https://doi.org/10.1002/hed.21342

PMid:20146332 

25. Lira RCP, Miranda FA, Guimarães MCM, Simões RT, Donadi EA, Soares CP, et al. BUBR1 expression in benign oral lesions and squamous cell carcinomas: correlation with human papillomavirus. Oncol Rep. 2010;23:1027-36.

https://doi.org/10.3892/or_00000729

PMid:20204288

26. Rizzardi C, Torelli L, Barresi E, Schneider M, Canzonieri V, Biasotto M, et al. BUBR1 expression in oral squamous cell carcinoma and its relationship to tumor stage and survival. Head Neck. 2011;33:727-33.

https://doi.org/10.1002/hed.21532

PMid:21069850 

27. Zhang X, Kim KY, Zheng Z, Bazarsad S, Kim J. Nomogram for risk prediction of malignant transformation in oral leukoplakia patients using combined biomarkers. Oral Oncol. 2017;72:132-9.

https://doi.org/10.1016/j.oraloncology.2017.07.015

PMid:28797449 

28. Kawakami M, Liu X, Dmitrovsky E. New Cell Cycle Inhibitors Target Aneuploidy in Cancer Therapy. Annu Rev Pharmacol Toxicol. 2019;59:361-77.

https://doi.org/10.1146/annurev-pharmtox-010818-021649

PMid:30110577 

29. Silva PMA, Ribeiro N, Lima RT, Andrade C, Diogo V, Teixeira J, et al. Suppression of spindly delays mitotic exit and exacerbates cell death response of cancer cells treated with low doses of paclitaxel. Cancer Lett. 2017;394:33-42.

https://doi.org/10.1016/j.canlet.2017.02.024

PMid:28249757 

30. Janssen A, Kops GJPL, Medema RH. Elevating the frequency of chromosome mis-segregation as a strategy to kill tumor cells. Proc Natl Acad Sci U S A. 2009;106:19108-13.

https://doi.org/10.1073/pnas.0904343106

PMid:19855003 PMCid:PMC2776415